Bioxytran (BIXT) Amortization - Intangibles (2022 - 2026)
Bioxytran (BIXT) posted Amortization - Intangibles of $2108.0 for Q1 2026, down 28.49% sequentially from $2948.0 in Q4 2025, and up 13.88% YoY from $1851.0 in Q1 2025.
Bioxytran (BIXT) Amortization - Intangibles (2022 - 2026) Analysis & Trends
Bioxytran has reported Amortization - Intangibles for 5 years, with the latest figure at $2108.0 in Q1 2026.
- Quarterly Amortization - Intangibles rose 13.88% year-over-year to $2108.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11801.0 (up 51.88% YoY) and the FY2025 annual result came in at $11544.0, up 45.21% from the prior year.
- Amortization - Intangibles fell to $2108.0 in Q1 2026 per BIXT's latest filing, from $2948.0 in the prior quarter.
- Over five years, Amortization - Intangibles peaked at $4236.0 in Q3 2025 and troughed at $514.0 in Q1 2023.
- A 5-year average of $1972.4 and a median of $1851.0 in 2025 frame the typical range for Amortization - Intangibles.
- The widest YoY moves for Amortization - Intangibles: up 314.93% in 2023, down 43.58% in 2023.
- Over 5 years, Amortization - Intangibles stood at $911.0 in 2022, then soared by 314.93% to $3780.0 in 2023, then slipped by 24.15% to $2867.0 in 2024, then gained by 2.83% to $2948.0 in 2025, then slipped by 28.49% to $2108.0 in 2026.
- According to Business Quant data, Amortization - Intangibles over the past three periods registered $2108.0, $2948.0, and $4236.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,108.00 |
| Dec 31, 2025 | 2,948.00 |
| Sep 30, 2025 | 4,236.00 |
| Jun 30, 2025 | 2,509.00 |
| Mar 31, 2025 | 1,851.00 |
| Dec 31, 2024 | 2,867.00 |
| Sep 30, 2024 | 1,516.00 |
| Jun 30, 2024 | 1,536.00 |
| Mar 31, 2024 | 2,031.00 |
| Dec 31, 2023 | 3,780.00 |
| Sep 30, 2023 | 1,803.00 |
| Jun 30, 2023 | 2,188.00 |
| Mar 31, 2023 | 514.00 |
| Dec 31, 2022 | 911.00 |
| Sep 30, 2022 | 911.00 |
| Jun 30, 2022 | 911.00 |
| Mar 31, 2022 | 911.00 |